Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 571 participants.

Also called NCT07575269

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 571 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07575269
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Ireland, Spain (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07575269. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-07 (actual); primary completion 2028-07-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
Acronym
FARADIGM
Condition
Paroxysmal Atrial Fibrillation (PAF)
Condition
Persistent Atrial Fibrillation
Intervention (Device)
FARAFLEX Mapping and Pulsed Field Ablation (PFA) System
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct07575269
Content hash
c5c62a15bad11e6dfea23f80be9fdadf6dc3b383bd24d7d6c428dc323a667db4